CD6 and syntaxin binding protein 6 variants and response to tumor necrosis factor alpha inhibitors in Danish patients with rheumatoid arthritis.
<h4>Background</h4>TNFα inhibitor therapy has greatly improved the treatment of patients with rheumatoid arthritis, however at least 30% do not respond. We aimed to investigate insertions and deletions (INDELS) associated with response to TNFα inhibitors in patients with rheumatoid arthr...
Guardado en:
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2012
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/945e5501aed1486d9b0f461d734cf69c |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:945e5501aed1486d9b0f461d734cf69c |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:945e5501aed1486d9b0f461d734cf69c2021-11-18T07:16:03ZCD6 and syntaxin binding protein 6 variants and response to tumor necrosis factor alpha inhibitors in Danish patients with rheumatoid arthritis.1932-620310.1371/journal.pone.0038539https://doaj.org/article/945e5501aed1486d9b0f461d734cf69c2012-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22685579/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>TNFα inhibitor therapy has greatly improved the treatment of patients with rheumatoid arthritis, however at least 30% do not respond. We aimed to investigate insertions and deletions (INDELS) associated with response to TNFα inhibitors in patients with rheumatoid arthritis (RA).<h4>Methodology and principal findings</h4>In the DANBIO Registry we identified 237 TNFα inhibitor naïve patients with RA (81% women; median age 56 years; disease duration 6 years) who initiated treatment with infliximab (n=160), adalimumab (n=56) or etanercept (n=21) between 1999 and 2008 according to national treatment guidelines. Clinical response was assessed at week 26 using EULAR response criteria. Based on literature, we selected 213 INDELS potentially related to RA and treatment response using the GeneVa® (Compugen) in silico database of 350,000 genetic variations in the human genome. Genomic segments were amplified by polymerase chain reaction (PCR), and genotyped by Sanger sequencing or fragment analysis. We tested the association between genotypes and EULAR good response versus no response, and EULAR good response versus moderate/no response using Fisher's exact test. At baseline the median DAS28 was 5.1. At week 26, 68 (29%) patients were EULAR good responders, while 81 (34%) and 88 (37%) patients were moderate and non-responders, respectively. A 19 base pair insertion within the CD6 gene was associated with EULAR good response vs. no response (OR=4.43, 95% CI: 1.99-10.09, p=7.211×10(-5)) and with EULAR good response vs. moderate/no response (OR=4.54, 95% CI: 2.29-8.99, p=3.336×10(-6)). A microsatellite within the syntaxin binding protein 6 (STXBP6) was associated with EULAR good response vs. no response (OR=4.01, 95% CI: 1.92-8.49, p=5.067×10(-5)).<h4>Conclusion</h4>Genetic variations within CD6 and STXBP6 may influence response to TNFα inhibitors in patients with RA.Sophine B KrintelLaurent EssiouxAssaf WoolJulia S JohansenEhud SchreiberTomer ZekharyaPinchas AkivaMikkel OstergaardMerete L HetlandPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 7, Iss 6, p e38539 (2012) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Sophine B Krintel Laurent Essioux Assaf Wool Julia S Johansen Ehud Schreiber Tomer Zekharya Pinchas Akiva Mikkel Ostergaard Merete L Hetland CD6 and syntaxin binding protein 6 variants and response to tumor necrosis factor alpha inhibitors in Danish patients with rheumatoid arthritis. |
| description |
<h4>Background</h4>TNFα inhibitor therapy has greatly improved the treatment of patients with rheumatoid arthritis, however at least 30% do not respond. We aimed to investigate insertions and deletions (INDELS) associated with response to TNFα inhibitors in patients with rheumatoid arthritis (RA).<h4>Methodology and principal findings</h4>In the DANBIO Registry we identified 237 TNFα inhibitor naïve patients with RA (81% women; median age 56 years; disease duration 6 years) who initiated treatment with infliximab (n=160), adalimumab (n=56) or etanercept (n=21) between 1999 and 2008 according to national treatment guidelines. Clinical response was assessed at week 26 using EULAR response criteria. Based on literature, we selected 213 INDELS potentially related to RA and treatment response using the GeneVa® (Compugen) in silico database of 350,000 genetic variations in the human genome. Genomic segments were amplified by polymerase chain reaction (PCR), and genotyped by Sanger sequencing or fragment analysis. We tested the association between genotypes and EULAR good response versus no response, and EULAR good response versus moderate/no response using Fisher's exact test. At baseline the median DAS28 was 5.1. At week 26, 68 (29%) patients were EULAR good responders, while 81 (34%) and 88 (37%) patients were moderate and non-responders, respectively. A 19 base pair insertion within the CD6 gene was associated with EULAR good response vs. no response (OR=4.43, 95% CI: 1.99-10.09, p=7.211×10(-5)) and with EULAR good response vs. moderate/no response (OR=4.54, 95% CI: 2.29-8.99, p=3.336×10(-6)). A microsatellite within the syntaxin binding protein 6 (STXBP6) was associated with EULAR good response vs. no response (OR=4.01, 95% CI: 1.92-8.49, p=5.067×10(-5)).<h4>Conclusion</h4>Genetic variations within CD6 and STXBP6 may influence response to TNFα inhibitors in patients with RA. |
| format |
article |
| author |
Sophine B Krintel Laurent Essioux Assaf Wool Julia S Johansen Ehud Schreiber Tomer Zekharya Pinchas Akiva Mikkel Ostergaard Merete L Hetland |
| author_facet |
Sophine B Krintel Laurent Essioux Assaf Wool Julia S Johansen Ehud Schreiber Tomer Zekharya Pinchas Akiva Mikkel Ostergaard Merete L Hetland |
| author_sort |
Sophine B Krintel |
| title |
CD6 and syntaxin binding protein 6 variants and response to tumor necrosis factor alpha inhibitors in Danish patients with rheumatoid arthritis. |
| title_short |
CD6 and syntaxin binding protein 6 variants and response to tumor necrosis factor alpha inhibitors in Danish patients with rheumatoid arthritis. |
| title_full |
CD6 and syntaxin binding protein 6 variants and response to tumor necrosis factor alpha inhibitors in Danish patients with rheumatoid arthritis. |
| title_fullStr |
CD6 and syntaxin binding protein 6 variants and response to tumor necrosis factor alpha inhibitors in Danish patients with rheumatoid arthritis. |
| title_full_unstemmed |
CD6 and syntaxin binding protein 6 variants and response to tumor necrosis factor alpha inhibitors in Danish patients with rheumatoid arthritis. |
| title_sort |
cd6 and syntaxin binding protein 6 variants and response to tumor necrosis factor alpha inhibitors in danish patients with rheumatoid arthritis. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2012 |
| url |
https://doaj.org/article/945e5501aed1486d9b0f461d734cf69c |
| work_keys_str_mv |
AT sophinebkrintel cd6andsyntaxinbindingprotein6variantsandresponsetotumornecrosisfactoralphainhibitorsindanishpatientswithrheumatoidarthritis AT laurentessioux cd6andsyntaxinbindingprotein6variantsandresponsetotumornecrosisfactoralphainhibitorsindanishpatientswithrheumatoidarthritis AT assafwool cd6andsyntaxinbindingprotein6variantsandresponsetotumornecrosisfactoralphainhibitorsindanishpatientswithrheumatoidarthritis AT juliasjohansen cd6andsyntaxinbindingprotein6variantsandresponsetotumornecrosisfactoralphainhibitorsindanishpatientswithrheumatoidarthritis AT ehudschreiber cd6andsyntaxinbindingprotein6variantsandresponsetotumornecrosisfactoralphainhibitorsindanishpatientswithrheumatoidarthritis AT tomerzekharya cd6andsyntaxinbindingprotein6variantsandresponsetotumornecrosisfactoralphainhibitorsindanishpatientswithrheumatoidarthritis AT pinchasakiva cd6andsyntaxinbindingprotein6variantsandresponsetotumornecrosisfactoralphainhibitorsindanishpatientswithrheumatoidarthritis AT mikkelostergaard cd6andsyntaxinbindingprotein6variantsandresponsetotumornecrosisfactoralphainhibitorsindanishpatientswithrheumatoidarthritis AT meretelhetland cd6andsyntaxinbindingprotein6variantsandresponsetotumornecrosisfactoralphainhibitorsindanishpatientswithrheumatoidarthritis |
| _version_ |
1718423679656787968 |